Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

–

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...

Antibody drug conjugate (HER2-TDC) (RG6148) Antibody drug conjugate (RG6109) Anti-MUC16 TDC (RG7882) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF MAb) CD20 x CD3 (RG6026) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cibisatamab (CEA x CD3) (RG7802) Cobimetinib (MEK inhibitor) (RG7421) Codrituzumab (anti–glypican 3 MAb) (CHU, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib (ROS1/TRK inhibitor) (RXDX-101, RG6268) Etrolizumab (RG7413) FAP-4-1BBL FP (RG7827) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Fixed dose combination SC pertuzumab + trastuzumab (anti-HER2 MAb) (RG6264) Glypican-3 x CD3 (CHU) HER2 x CD3 (RG6194) Idasanutlin (MDM2 antagonist) (RG7388) Individualized NeoAntigen Specific Immunotherapy (iNeST) (RG6180) Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6123) Monoclonal antibody (RG6160) Mosunetuzumab (CD20 x CD3) (RG7828) Obinutuzumab Pan-RAF inhibitor (RG6185) PD-1 x TIM3 (RG7769) PI3K inhibitor (GDC-0077, RG6114) PI3K inhibitor (RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor (CHU) Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Tiragolumab (anti-TIGIT MAb) (RG6058) Tocilizumab (RG1569) Vanucizumab (ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...

Clear All

View Results

Expand +

Tumor Type: Breast, Gastrointestinal, Genitourinary, Gynecologic, Hematology, Lung, Melanoma, Solid Tumor

Phase: PHASE II

Region:

Molecule: Polatuzumab vedotin (anti-CD79b ADC) (RG7596)

No results found. Please expand selection area
using the + icon at the top right and try again.

No results found. Please try again.

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.

Clear All

View Results

Current as of August 23, 2019. The trial information is taken from ClinicalTrials.gov. The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

These compounds and/or uses are investigational and have not been approved by the US Food and Drug Administration. Some molecules are currently being investigated for potential use in multiple tumor types. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use.

*Only Genentech/Roche molecules are shown in this column. Please see ClinicalTrials.gov website for a complete list of agents/interventions used in each study.

This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.

CancelOK

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

CancelContinue

The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.